Prognosis influence of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia with t(15;17)(q24;q21)

Figures & data

Table 1. Clinical characteristics and response to treatment of with t(15;17) APL patients.

Parameters	Total (n = 268)	t(15;17) with alone (n = 208)	t(15;17) with ACAs (n = 60)	P
Sex (male/female, cases)	147/121	112/96	35/25	0.538
Age [M [IQR]]	44 [32, 55]	44 [33, 55]	43 [30, 54]	0.641
<60 years [cases, (%)]	220(82)	172(83)	48(80)
≥60 years [cases, (%)]	48(18)	36(17)	12(20)
BM percentage [%, M (IQR)]	85.00 [78.00, 90.00]	85.00 [78.38, 90.00]	84.25 [78.00, 89.00]	0.582
WBC [10^9/L, M(IQR)]	2.01 [1.10, 10.77]	2.16 [1.16, 11.75]	1.85 [1.00, 6.50]	0.179
HB [g/L, M (IQR)]	91.00 [72.00, 108.00]	91.00 [74.00, 108.00]	87.00 [68.00, 108.25]	0.462
PLT [10^9/L, M (IQR)]	27.50 [15.75, 50.00]	28.00 [17.00, 54.25]	23.00 [13.75, 40.00]	0.154
FIB [g/L, M (IQR)]	1.46 [0.96, 2.34]	1.52 [0.97, 2.27]	1.32 [0.87, 2.55]	0.644
APTT [s, M (IQR)]	26.80 [24.60, 29.75]	26.95 [24.60, 29.90]	26.60 [24.43, 28.90]	0.530
PT [s, M (IQR)]	13.05 [11.90, 14.60]	13.00 [11.90, 14.60]	13.20 [12.10, 14.45]	0.629
D-Dimer [ug/L, M (IQR)]	11950.00 [4890.00, 26060.00]	11847.00 [4605.00, 25552.50]	12230.00 [6400.00, 29620.00]	0.426
LDH [U/L, M (IQR)]	323.50 [226.75, 567.75]	325.00 [226.50, 571.50]	305.00 [227.00, 512.00]	0.804
PML::RARa form, n (%)				0.362
L form	161(60)	128(62.5)	33(55)
<60 years/≥60 years(cases)	136/25	107/21	29/4	0.544
S form	107(40)	80(39.5)	27(45)
<60 years/≥60 years(cases)	84/23	65/15	19/8	0.234
Classification of risk, n (%)				0.373
Low-intermediate	198(74)	151(73)	47(78)
High	70(26)	57(27)	13(21)
Response of treatment, n (%)
Hematologic CR	246(92)	165(79)	51(85)	0.328
Total death	26(10)	19(9)	7(12)	0.559
Early death	22(8)	18(9)	4(7)	0.820
Relapse	27(11)	19(10.0)	8(14)	0.367

Note: M: median; IQR: interquartile range [P25, P75]; WBC: white blood cell; PLT: platelet; HB: hemoglobin; FIB: fibrinogen; APTT: activated partial thromboplastin time; PT: prothrombin time; LDH: lactate dehydrogenase; CR: complete remission.

Figure 1. Survival outcomes for APL patients according to the presence of ACAs or trisomy 8. (A) OS in the ACAs group; (B) DFS in the ACAs group; (C) OS in the trisomy 8 group; (D) DFS in the trisomy 8 group.

Figure 2. Survival outcomes for APL patients in the subgroup of age ≥60 years. (A) OS in the patients with aged ≥60 years subgroup; (B) DFS in those with aged ≥60 years subgroup.

Figure 3. Survival outcomes for APL patients in various treatment subgroups according to the presence or absence of ACAs. (A) OS in the ATRA + ATO/RIF subgroup; (B) DFS in the ATRA + ATO/RIF subgroup group; (C) OS in the ATRA + ATO/RIF + CH subgroup; (D) DFS in the ATRA + ATO/RIF + CH subgroup; (E) OS in ATRA + CH subgroup; (F) DFS in ATRA + CH subgroup.